Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2010 · New England Journal of Medicine · 15K citations
https://doi.org/10.1056/nejmoa1003466
F
F. Stephen Hodi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.5K
Papers
161.5K
Citations
156
h-index
499
i10-index
F. Stephen Hodi is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 156, co-authored 1294 publications.
ORCID: 0000-0001-6825-091XPapers by this author
worksOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · New England Journal of Medicine · 5,300 citations
https://doi.org/10.1056/nejmoa1709684
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
2014 · Nature · 5,183 citations
https://doi.org/10.1038/nature14011
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019 · New England Journal of Medicine · 3,642 citations
https://doi.org/10.1056/nejmoa1910836
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
2016 · Nature Communications · 1,522 citations
https://doi.org/10.1038/ncomms10501
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
2017 · Cell · 1,437 citations
https://doi.org/10.1016/j.cell.2017.08.027
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat